



# OFFICE OF INSPECTOR GENERAL

## U.S. Agency for International Development

### MEMORANDUM

**DATE:** January 15, 2026

**TO:** USAID, Performing the Duties of Administrator and Chief Operating Officer, Eric Ueland

USAID, Acting Chief Financial Officer, Douglas A. Pitkin

**FROM:** USAID OIG Africa Regional Office, Audit Director, Ryan Werner /s/

**SUBJECT:** Financial Audit of USAID Resources Managed by Mission for Essential Drugs and Supplies in Kenya Under Multiple Awards, January 1 to December 31, 2024  
(Report No. 4-615-26-010-R)

This memorandum transmits the final audit report on USAID resources managed by Mission for Essential Drugs and Supplies (MEDS) under 1) USAID Dawa Za Ubora Project, contract 72061521C00003 and 2) USAID Jamii Tekelezi Project, subaward 72061521CA00009 through Christian Health Association of Kenya (CHAK). MEDS contracted with the independent audit firm Ernst & Young LLP, Nairobi, Kenya to conduct the audit. The audit firm stated that it performed its audit in accordance with the International Standards on Auditing (ISAs) in conjunction with U.S. Government Auditing Standards issued by the Comptroller General of the United States (GAGAS). However, it did not have an external peer review program that fully satisfy the standards' requirements. The audit firm is responsible for the enclosed report and the conclusions expressed in it. We do not express an opinion on MEDS's schedule of expenditures on USAID awards; the effectiveness of its internal control; or its compliance with the award, laws, and regulations.<sup>1</sup>

The audit objectives were to (1) express an opinion on whether the schedule of expenditures of USAID awards for the period audited, was presented fairly, in all material respects; (2) evaluate MEDS's internal controls; (3) determine whether MEDS complied with award terms and applicable laws and regulations; (4) review the indirect cost rate; and (5) review the implementation status of the prior period recommendations.

To answer the audit objectives, Ernst & Young LLP (1) audited the schedule of expenditures of USAID awards including the budgeted amounts by category and major items and the revenues

---

<sup>1</sup> We reviewed the audit firm's report for conformity with professional reporting standards. Our desk reviews are typically performed to identify any items needing clarification or issues requiring management attention. Desk reviews are limited to review of the audit report itself and excludes review of the auditor's supporting working papers; they are not designed to enable us to directly evaluate the quality of the audit performed.

received from USAID for the period covered by the audit and the costs reported by MEDS as incurred from January 1 to December 31, 2024; (2) evaluated the control environment, the adequacy of the accounting systems, and control procedures that pertain to MEDS's ability to report financial data consistent with the assertions embodied in each account of the schedule of expenditures of USAID awards; (3) identified the award terms and pertinent laws and regulations and determined which of those, if not observed, could have a direct and material effect on the schedule of expenditures of USAID awards; (4) determined the review of the indirect cost rate was not applicable; and (5) reviewed of the implementation status of the prior period recommendations. MEDS reported expenditures of \$7,186,876 in USAID funds during the audited period.

The audit firm concluded the schedule of expenditures of USAID awards presented fairly, in all material respects, program revenues and costs incurred under the awards for the period audited. The audit firm identified \$3,070 in ineligible questioned costs; no material weaknesses in internal control; and one instance of material noncompliance specifically related to the questioned costs identified. Since the questioned costs did not meet the OIG's established threshold of \$25,000 for making a recommendation, we are not making a recommendation for the questioned costs and specifically related noncompliance instance. Nevertheless, we suggest that USAID determine the allowability of the \$3,070 in questioned costs and recover any amount determined to be unallowable.

Accordingly, we are not making any recommendations.

OIG does not routinely distribute independent public accounting reports beyond the immediate addressees because a high percentage of these reports contain information restricted from release under the Trade Secrets Act, 18 U.S.C. 1905 and Freedom of Information Act Exemption Four, 5 U.S.C. 552(b)(4) ("commercial or financial information obtained from a person that is privileged or confidential"). In addition, USAID OIG has determined that this transmittal memo and the enclosed report are not subject to notification and reporting requirements under Section 5274 of the National Defense Authorization Act.<sup>2</sup>

---

<sup>2</sup> The James M. Inhofe National Defense Authorization Act for Fiscal Year 2023 Pub. L. No. 117-263, § 5274. Please direct related inquiries to [oignotice\\_ndaa5274@usaid.gov](mailto:oignotice_ndaa5274@usaid.gov).